Helm AG

Disclosure context

As a private AG, HELM files HGB single-entity and consolidated statements with the German Federal Gazette (Unternehmensregister). The index shows consolidated statements for FY2021, FY2022, FY2023 and FY2024; FY2024 was published Oct–Nov 2025. The full statements were not accessible in this run (paywalled via North Data or Statista). The FY2025 statements had been approved at the May 2026 AGM but were not yet published at the time of writing. HELM publishes only headline turnover, segment and region percentages, and headcount. Most line items below are therefore not publicly disclosed, and none are estimated.

Income statement

Sources and caveats:

FY2023 revenue — conflicting sources: HELM's own September 2024 press release (Ancom Nylex) gives EUR 5.9 bn. cio.de's company profile gives EUR 8,022 M. The higher figure most likely reflects a pre-consolidation turnover measure: HELM historically reported both "turnover before consolidation" and "external turnover"; in FY2014 these were EUR 9.76 bn and EUR 5.05 bn. The EUR 5.9 bn company figure is used here.

FY2024 revenue: EUR 5.8 bn per Wikipedia (citing the North Data register extract) and the hamburg.de profile.

FY2025 revenue: EUR 4.7 bn per helmag.com.

FY2023 EBIT: EUR 115 M per cio.de. This is a secondary source with an unclear basis (it may be pre-consolidation).

FY2023 net result: a net loss of roughly EUR 4.5 M per the Statista summary of HELM's "Jahresergebnis". It is unclear whether this is the group or the parent entity. Note the apparent tension with EUR 115 M EBIT; impairments, financial expenses or equity-method losses (e.g., ramp-up of lithium or Qore) could reconcile the two, but this cannot be verified.

FY2021 and FY2022: not publicly disclosed in accessible sources. FY2020 turnover was EUR 4.1 bn (Deutsche Wirtschafts Nachrichten, Jan 2022).

Per-share data: not applicable (no listed shares).

Long-run reference points

Sources: FY2014 from CHEManager, 20 May 2015; FY2020 from DWN; FY2023 from the HELM release, cio.de and Statista; FY2024–25 as above. The FY2023 "before consolidation" figure assumes the cio.de value follows that definition, which is an analyst interpretation.

Margins and growth (computed only where inputs exist)

• FY2023 EBIT margin = 115 / 5,900. This mixes sources and should be read as indicative only.

Revenue CAGR: FY2023–FY2025 = -10.7% p.a. (5.9 → 4.7 bn). FY2020–FY2025 = +2.8% p.a. (4.1 → 4.7 bn). FY2014–FY2025 (external) = -0.7% p.a.

Reference margins (FY2014): EBITDA margin on external sales 3.7%; net margin 2.8%.

Balance sheet

All items are not publicly disclosed in accessible sources. Statista holds an "Eigenmittel" (own funds) series for 2004–2019, but the values are paywalled. The FY2014 commentary emphasised that HELM's equity base provides "stability and independence", and the group historically carried a conservative, bank-funded balance sheet. Share capital is EUR 100 M.

Cash flow

Not publicly disclosed. Disclosed investment commitments give some indication of capital deployment:

Qore: USD 300 M facility, shared with Cargill; HELM's share is not disclosed.

LevertonHELM: full buy-out in 2024; price not disclosed.

Ancom Nylex: up to approximately RM 96.2 M (roughly EUR 20 M at about 4.7 RM/EUR) for up to 10%.

Unium: staged acquisition 2021–2026; price not disclosed.

Historic: more than EUR 250 M invested in FY2014.

Ratios

All balance-sheet ratios are not publicly disclosed. Revenue per employee is computed from published turnover and headcount; FY2024 uses the average headcount.

Commentary on trends, inflections and drivers

Top-line contraction since 2023. Turnover fell from EUR 5.9 bn (FY2023) to EUR 5.8 bn (FY2024) and then sharply to EUR 4.7 bn (FY2025), a 19% decline. Four drivers are consistent with the public record, though HELM has not published a bridge:

1. Commodity price deflation. Methanol, HELM's largest revenue line, and broad petrochemical prices normalised after the 2021–22 spike. Because HELM records trading revenue gross, price deflation flows directly into turnover even when gross margin in euros is stable.

2. Agchem destocking and generic price collapse. The 2023–2025 global crop-protection downturn was characterised by Chinese active-ingredient overcapacity and channel destocking. This hit generic-actives marketers in particular.

3. Portfolio pruning. The exit from European classic crop protection (from 1 Jul 2025) removed a revenue stream for half of FY2025. The Richter-Helm BioTec exit in 2024 and the pharma carve-out also changed the perimeter.

4. Possible FX translation from a weaker USD. A large share of trading is USD-denominated and 37% of sales are in the Americas.

Profitability. The only recent datapoints — roughly EUR 115 M EBIT and a small net loss in FY2023 — point to a business near break-even at the bottom line. This is a sharp contrast with FY2014's EUR 141.6 M net income. The likely causes are (a) start-up losses and impairments in transformation assets (lithium prices collapsed through 2023–24, which would pressure LevertonHELM's valuation and inventory), (b) agchem margin compression, and (c) restructuring. This interpretation is inferential.

Inflection to watch. FY2026 will be the first full year without European crop protection and with Qore producing (from Jul 2025). It will also be the first full year with Unium fully owned. Revenue stabilisation around EUR 4.5–5.0 bn would indicate the cycle trough has passed. This is an analyst monitoring threshold, not company guidance.

Management guidance

None published. Qualitative direction from 2025–26 statements:

• continued transformation, with explicit emphasis on the "new lithium division";

• global process optimisation;

• deeper engagement with the automotive industry (CEO statement, May 2026);

• growth through partnerships (Parijat, Aug 2026).

Consensus expectations

None. HELM has no analyst coverage.

Bull case

1. Cycle trough plus perimeter reset. FY2025's EUR 4.7 bn likely marks the bottom: European crop protection is gone, and commodity prices and agchem destocking have normalised. A leaner organisation of about 1,810 staff operating on a recovering volume base could restore profitability well above the FY2023 near-break-even level.

2. Transformation assets come online simultaneously. Qore (66 kt/yr, with BASF and LYCRA as customers), full ownership of Unium, validated NESI recycling and exclusive US bio-ECH rights add higher-margin, differentiated revenue that is less exposed to commodity spreads.

3. Asia optionality at low capital cost. The Parijat partnership (brand licence, toll manufacturing, distribution swap) and the Ancom Nylex stake extend HELM into India and South-East Asia without heavy investment.

Bear case

1. Structural revenue decline. Turnover fell 20% in two years (EUR 5.9 bn → 4.7 bn). The core methanol and generic-agchem franchises face producer disintermediation (e.g., CAC using its own distributor) and Chinese overcapacity.

2. Lithium is a capital trap. European battery demand has disappointed and lithium prices remain far below 2022 peaks. LevertonHELM is sub-scale, and a refinery FID could absorb significant capital for uncertain returns.

3. Opacity and earnings quality. The FY2023 net loss, inconsistent revenue figures (EUR 5.9 bn vs. 8.0 bn), no published targets, and frequent changes in the board and extended management make value creation hard to verify for lenders, partners and potential co-investors.

Key catalysts and monitorables (next 12 months)

Analyst verdict

HELM AG is a century-old Hamburg trading house in the middle of a deliberate, family-funded metamorphosis. On the evidence available, it is a sound franchise with an unproven second act. The legacy engine is large and globally distributed: methanol marketing under the Proman partnership, chemical intermediates, generic agrochemicals and pharma sourcing generated EUR 4.7 billion of turnover in FY2025 across Europe (51%), the Americas (37%) and Asia (12%). But that engine is shrinking. Turnover has fallen about 20% since FY2023, the most recent profit datapoint (FY2023) shows a marginal loss, and the company has just exited European classic crop protection.

Against this, HELM has assembled a portfolio of transformation assets that few private distributors could fund: a commercially operating bio-BDO plant with Cargill, a wholly owned UK lithium refiner with validated recycling technology, a UK biologicals platform, a digital agronomy app with Indian reach, and a fresh set of Asian partnerships. Governance has been visibly upgraded, with an Otto Group CEO as chair and automotive and catalyst veterans added in 2026, to oversee exactly this pivot.

The decisive question is capital allocation discipline. The lithium refinery decision in particular will determine whether HELM becomes a differentiated European critical-materials and bio-chemicals player or ties up its balance sheet in a structurally oversupplied market. For counterparties — suppliers, customers, lenders and potential JV partners — HELM remains a credible, well-connected and conservatively owned counterparty. Its opacity, however, warrants requesting the FY2024 and FY2025 audited HGB statements before extending material credit or entering capital-intensive joint ventures.

Overall stance: stable franchise, negative revenue momentum, high strategic optionality, elevated execution risk.